Cutaneous lupus erythematosus: Update of therapeutic options

Kuhn, Annegret; Ruland, Vincent; Bonsmann, Gisela

doi:10.1016/j.jaad.2010.06.017

Cited by 120 publications

(85 citation statements)

References 170 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The results of a randomized double-blind study found no significant difference between the effectiveness of 0.05 % clobetasol propionate and 0.1 % tacrolimus ointment. Several small, and generally uncontrolled, studies have been conducted, sometimes with contradictory results [14]. Their use is warranted in inflammatory types of CLE and in SCLE; they may also be used on the face and in intertriginous zones due to the risk of atrophy and telangiectasias.…”

Section: Topical Therapymentioning

confidence: 99%

Lupus erythematosus. Part II: Clinical picture, diagnosis and treatment

Ziemer

Milkova

Kunz

2014

J Deutsche Derma Gesell

View full text Add to dashboard Cite

SummaryLupus erythematosus (LE) is an important dermatologic autoimmune disease. In many respects, it may be regarded as a model autoimmune disease due to its spectrum of autoimmune antibodies and involvement of different organ systems, as well as response to immunosuppressive agents which target B cells and T cells and their cytokines. A recently published article in this Journal summarized the most important knowledge about epidemiology, genetics, and immunology of LE. Here, the different clinical manifestations, diagnostic procedures and current therapeutic approaches will be described. Special emphasis is placed on different cutaneous manifestations of LE. In regard to treatment, the classic treatment approaches such as corticosteroids, methotrexate, chloroquine and hydroxychloroquine will be described. Lastly, new therapeutic approaches with specific monoclonal antibodies which are currently used in systemic LE, such as belimumab (Benlysta®), will be addressed. The most recent developments in this area could have implications even for purely cutaneous forms of LE.

show abstract

Section: Topical Therapymentioning

confidence: 99%

Lupus erythematosus. Part II: Clinical picture, diagnosis and treatment

Ziemer

Milkova

Kunz

2014

J Deutsche Derma Gesell

View full text Add to dashboard Cite

show abstract

“…Pelle and Werth reviewed 8 separate case series that reported a total of 171 patients with various forms of cutaneous lupus treated with thalidomide.The overall response rate was 85%, with complete resolution in 59%; the response rates for discoid lupus erythematosus and subacute cutaneous lupus erythematosus were comparable at 90.3% and 82.4%, respectively [2]. Thalidomide has also been used to effectively treat refractory tumid lupus erythematosus [2,9], but the drug has not been as successful in treating lupus panniculitis [2], Coelho and colleagues reported a complete or partial response in 99% of patients with all types of cutaneous lupus treated with thalidomide (100mg daily tapered to 50mg daily or less when clinically feasible). Two thirds of patients with lupus panniculitis, however, had no response to treatment [2].…”

Section: Lupus Erythematosusmentioning

confidence: 99%

Forgive sins: rise of thalidomide

Inakanti¹,

Kumar²

2014

Our Dermatol Online

View full text Add to dashboard Cite

Thalidomide was originally used as a Wonder Drug to treat morning sickness and insomnia in pregnant women in late 1950s. It became apparent in early 1960s that thalidomide treatment resulted in severe birth defects in thousands of children. Then it was banned in most of countries. Later on discovered anti-inflammatory and anti-angiogenic properties of Thalidomide proved to be useful for treatment of leprosy and multiple myeloma. A series of immunomodulatory drugs created by chemical modification of thalidomide have been developed to overcome the original devastating side effects. It's being investigated extensively as a treatment for many other severe cutaneous disorders and advanced cancers. We briefly review pharmacological and the therapeutic profile of thalidomide.

show abstract

“…Situations with more severe involvement can be approached with systemic steroids and hydroxychloroquine [19] [20] [21] [22]. This paper aims to present a rare case of an elderly man with SCLE, with a focus on the diagnosis of this pathology in a patient with sex and age opposed to what is usually found in literature.…”

Section: Introductionmentioning

confidence: 99%

Subacute Cutaneous Lupus Erythematosus in Older Man: Case Report

Martins¹,

Miguel²,

Anjos³

et al. 2017

JBM

View full text Add to dashboard Cite

Systemic lupus erythematosus (SLE) is an autoimmune disease that affects mainly women, presents several clinical manifestations and has no known exact cause. The skin is one of the organs that can be affected, with subacute cutaneous lupus erythematosus (SCLE) being one of the classifications according to cutaneous lupus erythematosus lesions. SCLE is commonly found in young to middle age women and carries characteristics related to sun exposure. In this report, there is a rare case of a male and elderly patient that presents SCLE subgroup initially asymptomatic, with subsequent appearance of macular skin lesions and vitiligo appearance. This is an important case to alert health professionals that the disease can manifest itself and open its clinical profile even in patients of sex and unusual ages.

show abstract

Cutaneous lupus erythematosus: Update of therapeutic options

Cited by 120 publications

References 170 publications

Lupus erythematosus. Part II: Clinical picture, diagnosis and treatment

Lupus erythematosus. Part II: Clinical picture, diagnosis and treatment

Forgive sins: rise of thalidomide

Subacute Cutaneous Lupus Erythematosus in Older Man: Case Report

Contact Info

Product

Resources

About